Autoimmune pancreatitis (AIP) is an increasingly recognized disease entity, but data in children are limited. AIP presentation and outcome in children might differ from the adult experience. We aim to determine the characteristic features of AIP in children.
INTRODUCTION
Autoimmune pancreatitis (AIP) is a distinctive type of pancreatitis fi rst described in 1961 by Sarles et al. ( 1 ) as a particular form of chronic pancreatitis (CP) that was associated with hypergammaglobulinemia. In 1995, Yoshida et al. ( 2 ) labeled this newly recognized disease "autoimmune pancreatitis. " ICDC (International Consensus Diagnostic Criteria) for AIP ( 3 ) were established in 2011 and are mainly based on a combination of fi ve cardinal features including pancreas histology and imaging fi ndings, positive serology, presence of other autoimmune or infl ammatory organ diseases, and prompt response to corticosteroids ( 3 ) . AIP in adults is classifi ed into two subgroups, characterized by diff erences in epidemiology, clinical profi le, histopathology, natural history, and outcome ( 4 ) . A high prevalence of AIP type 1 (lymphoplasmacytic sclerosing pancreatitis) is observed in Asia, whereas AIP type 2 (idiopathic duct-centric pancreatitis) mainly occurs in Western countries. A defi nitive diagnosis of idiopathic duct-centric pancreatitis requires histo logic examination, whereas lymphoplasmacytic sclerosing pancreatitis can be diagnosed without ( 5 ) .
In children, reports about AIP are scarce with a few published cases and case series (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . At the present time, pediatric gastroenterologists rely on the adult AIP guidelines to diagnose and manage AIP in children. However, initial observations and case reports suggest that the clinical presentation of AIP is diff erent in children compared with adults, and that exclusive use of adult criteria may lead to underdiagnosis of AIP in children.
We aimed to summarize current available data to support identifi cation of AIP in children, as AIP is the only form of CP for which targeted (anti-infl ammatory) treatment is available. Th ough there are no data exploring the long-term outcome of pediatric AIP patients in a systematic manner, it is conceivable that treatment may aff ect the long-term outcome of these patients. Furthermore, summarizing the characteristic features of AIP in children is needed to facilitate stratifi cation of these patients for future research studies.
In order to achieve these aims, we: (i) reviewed the literature to extract common characteristic features of children with a diagnosis of AIP and (ii) summarized characteristics reported in children with a diagnosis of AIP who are part of the largest international multicenter study of acute recurrent and chronic pancreatitis in children (INSPPIRE); this summary included several AIP cases collected at the Cliniques Universitaires St-Luc (CUSL) in Brussels, Belgium.
METHODS

Literature review
An electronic systematic literature search of PubMed (1946 on), Embase (1980 on), and CENTRAL (Cochrane Central Register of Controlled Trials) was performed up to September 2016. Th e key search terms included: "pediatric, " "children, " "lymphoplasmacytic sclerosing pancreatitis, " "idiopathic duct centric pancreatitis, " and "autoimmune pancreatitis. " Th e search was limited to human studies without any language restriction. Data concerning epidemiology (gender, age at presentation, ethnic origin), clinical symptoms, blood work, imaging and histologic fi ndings, associated diseases, treatment, and outcome were extracted and summarized.
Data collection from INSPPIRE and CUSL
Th e INSPPIRE database collects data on demographics, clinical presentation, and longitudinal follow-up of children (onset of illness <19 years of age) with acute recurrent pancreatitis and CP from 18 participating international centers. We collected baseline and follow-up data from children that were assigned a diagnosis of AIP by the pediatric gastroenterologist of each participating center from 1 September 2012 to 31 December 2015. Th e collected information included age, gender, medical history, family history, clinical symptoms at presentation, biochemical results, imaging, histopathology, therapeutic interventions, treatment, and outcome. Similarly, all pediatric patients with a diagnosis of AIP who were followed at CUSL and who were part of the pediatric onset (<18 years) pancreatitis registry (1 January 2000 and 1 July 2015) were included. All participating centers have obtained approval from their institutional review boards. Consent was obtained from all participants or their parents for children <18 years.
Statistics
Summary data were presented as mean and s.d. for normaldistributed data or median and interquartile ranges for nonnormally distributed data. Fisher's exact test was used for categorical variables and t -test analysis of variance was used for continuous variables. A P value of <0.05 was considered to be statistically signifi cant.
RESULTS
Pediatric AIP literature review and cases from the INSPPIRE and CUSL database
A retrospective analysis of the literature identifi ed 19 publications reporting 30 pediatric AIP cases (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Furthermore, 14 of the 361 (3.9%) children enrolled in INSPPIRE were diagnosed with AIP by Pediatric Pancreatologists working in the participating centers. An additional 4 patients were recruited at CUSL.
Epidemiology and clinical presentation
AIP was found in patients with Caucasian, African, and Asian background, with slight male preponderance (23/43, 53% male). Median age at diagnosis was 13 years (range: 2-17 years).
Acute abdominal pain (43/47, 91%) and/or obstructive jaundice (20/47, 42%) were the most commonly reported clinical symptoms at diagnosis. ( Table 1 )
Diagnostic evaluation
At the time point of diagnosis, an increase in amylase (median: 1.7× upper limit of normal (ULN), interquartile range (IQR): 1.3-4× ULN) and lipase (median: 4× ULN, IQR: 2.4-11xULN) was observed in about half of the patients (10/23, 43% and 14/26, 54% respectively). A positive serology for IgG4 was found in only 22% (9/40) of the patients (median: 1.9× ULN, IQR: 1.2-2.5× ULN). Th ough not specifi c for AIP, increased levels of antinuclear antibody (ANA) were present in 29% (7/24) of the cases ( Table 2 ) .
Imaging fi ndings were abnormal in all reported patients ( Table 2 and Figure 1 ). Transabdominal ultrasound was oft en the fi rst available imaging modality. A hypoechoic and enlarged pancreas was described in 83% (39/47) children with an established PANCREAS AND BILIARY TRACT VOLUME 112 | OCTOBER 2017
Scheers et al. diagnosis of AIP. In patients presenting with jaundice a proximal dilatation of the common bile duct (CBD) narrowing distally toward the pancreatic head was found in all cases. In all AIP patients magnetic resonance cholangiopancreatography (MRCP) imaging frequently showed global (17/47, 30%) or focal enlargements of the pancreas (25/47, 53%), demonstrated as hypointense areas on T1-weighted images. Irregularities of the main pancreatic duct were the most reported features (30/47, 64%), followed by a narrowed CBD (stricture or tapering, 26/47, 55%). A "capsule-like rim" (halo sign) was found in 5 of 32 children (16%). Five children of the INSPPIRE/CUSL cohort and 7 published cases underwent an endoscopic retrograde cholangiopancreatography (ERCP). ERCP fi ndings correlated with those of MRCP in 11 patients; one patient showed narrowing of the CBD in ERCP that was not visualized on MRCP.
Interpretable histologic results were available for 26 children ( Table 2 and Figure 2 ); of these, 16 were obtained using endo- 
Other organ involvement
AIP as part of an IgG4-related multisystemic disease was uncommon (2/45, 4%). Twelve AIP children (12/45, 27%) developed other autoimmune/infl ammatory diseases including Crohn's disease, ulcerative colitis, glomerulonephritis, and hemolytic anemia ( Table 3 ) .
Therapy
Th e main treatment approach to AIP was the use of prednisone. Th e doses and duration of corticosteroid regimen diff ered signifi cantly among centers. Prednisone doses ranged from 1 to 1.5 mg/kg/day with a maximum of 30 to 120 mg/day orally for 15 to 50 days in adolescents, followed by a progressive taper over 2 to 24 months. Eight children (8/46, 17%) were clinically monitored, but did not receive any corticosteroid therapy ( Table 4 ).
Response to therapy and early disease recurrence
Patients with AIP showed good short-term clinical response to corticosteroids (27/29, 93%) defi ned as clinical symptom resolution. Th e 8 patients who did not receive corticosteroids improved without further treatment. Insuffi cient data were available to analyze the time delay between the start of corticosteroid treatment and symptom resolution or to compare the time of clinical response between corticosteroid-treated and untreated patients. Imaging reevaluation, when done ( n =12/29 cases in literature and n =13/18 INSPPIRE/CUSL), was performed 1 to 11 months aft er treatment initiation and showed resolution of the initial radiologic fi ndings in all but 4 children. AIP recurrence was documented for 8/39 patients (17%), 6 of those had been previously treated with corticosteroids. Two of the six children with AIP relapse had only a partial response to the induction course but were successfully brought in remission aft er adding mycophenolate mofetil or 6-mercaptopurine, respectively.
Pancreatic function and long-term outcome
Th e reported median follow-up time was 21 months (IQR: 12.5-48) following prednisone induction as compared with 33 months (IQR: 14-48.5) for those not treated with corticosteroids ( P =0.42). Impaired exocrine function requiring pancreatic enzyme replace- ( Table 5 ).
DISCUSSION
AIP is a distinct form of pancreatitis that also occurs in children. By utilizing data from a large pediatric multicenter cohort study and information from previously reported cases, we have now derived the characteristic features of AIP in children. Th is comprehensive report will enable us to recognize pediatric patients with AIP that will stimulate further studies. According to our fi ndings, a diagnosis of AIP in children can be established based on the combination of specifi c clinical symptoms 
. Pancreas histopathology in pediatric autoimmune pancreatitis (AIP). Representative histopathologic features on pancreas core biopsies in children with autoimmune pancreatitis (hematoxylin and eosin (H&E) staining). ( a ) Dense lymphoplasmacytic infi ltration of the major papilla (original magnifi cation ×20). ( b ) Negative IgG4 staining of the plasma cells (original magnifi cation ×20). ( c ) Granulocytic epithelial lesion (arrow) and focal epithelial duct destruction (dashed arrow). The chorion is infi ltrated by lymphoplasmatic cells (original magnifi cation ×20). ( d ) Storiform fi brosis (original magnifi cation ×40).
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Characteristic Features of Pediatric AIP
at presentation and distinct fi ndings on cross-sectional imaging. Th is is in contrast to adult diagnostic AIP criteria that are much more comprehensive and based on HISORt ( h istology, i maging, s erology, the presence of o ther organ involvement, and r esponse to t herapy) criteria. Th e majority of children had symptoms of abdominal pain and/or obstructive jaundice in combination with focal pancreas enlargement, main pancreatic duct irregularities, and distal CBD narrowing on cross-sectional imaging. In fact abdominal pain, weight loss, and fatigue were more consistently reported in children (89-93%, 33-38%, and 14-44% respectively) than in adults, with 60-75% ( 4 ) of adult AIP patients presenting with painless jaundice, 15% with weight loss, and 9% with fatigue ( 25 ) . Th ough most of the imaging fi ndings of the pancreas are not specifi c for AIP, in combination with the clinical symptoms, however, certain fi ndings as listed in Table 2 are highly suggestive of AIP. A capsule-like rim enhancement of the pancreas was infrequent in children but its occurrence appears to be pathognomonic for the disease. A pancreatic head enlargement or nonencapsulated mass lesions have been reported more frequently. Although rare, a focal pancreas enhancement needs to be diff erentiated from pancreatic malignant tumors such as pancreatoblastoma or solid pseudopapillar epithelial neoplasms that are oft en encapsulated and express cystic and solid components. Lymphoma is another very rare, differential cause for focal pancreas enhancements. Compared with adults ( 4 ), focal rather than diff use pancreas enlargements were more frequent in children. Main pancreatic duct irregularities and distal CBD narrowing are nonspecifi c fi ndings and might also be seen in patients with CP or biliopancreatic diseases of any other etiology or even in primary sclerosing cholangitis type 1 ( 26 ), though adults now include this specifi c type of primary sclerosing cholangitis to the diagnostic criteria for AIP ( 27 ) . More detailed description of the pancreas and ductal pathology using cross-sectional imaging is challenged by the limitations of the MRCP resolution in young children ( 14 ) and the less frequent use of ERCP compared with adults ( 28 ) .
Increased serum IgG4 is very suggestive of AIP in adults, but this marker is of limited value as only 22% of the children had IgG4 levels above the ULN. In comparison, about 65% of adult AIP type 1 and 25% of adult AIP type 2 patients have elevated IgG4 levels. Th is suggests that children may more commonly follow the disease presentation of AIP type 2 or may have a distinct AIP pattern that may not necessarily fall into either category.
A diagnosis of AIP can be confi rmed by the histopathological identifi cation of pathognomonic and well-described features of an autoinfl ammatory process in the pancreas tissue specimen. Frequent fi nding of granulocytic epithelial lesion in pediatric pancreas tissue specimen would be consistent with type 2 AIP as per adult criteria. However, because of the increased clinical recognition of AIP as well as a growing familiarity with AIP-type imaging fi ndings, adult gastroenterologists oft en times waive a histopathological diagnosis and start a trial with corticosteroids that itself is used as a diagnostic criterion to confi rm the diagnosis of AIP ( 3,4 ) .
Th e distinction of two AIP subgroups such as those described in adults is diffi cult to establish in children. Only one child had autoimmune pancreatitis in the context of an IgG4-related systemic disease and could thus clearly be classifi ed as having an AIP type 1. IgG4 serology and immunostaining is rarely positive in children with AIP. Although granulocytic epithelial lesion is more frequently found in the pancreas of children with AIP compared with adults, histopathological features of pediatric AIP oft en include a combination of granulocytic epithelial lesion, lymphoplasmacytic infi ltration, and fi brosis. If adult AIP criteria were applied to the pediatric AIP population, children would most likely be classifi ed as having type 2 AIP. However, as histology of pancreas biopsies in children with AIP have not yet been validated in relation to the disease phenotype ( 3, 8 ) , we cannot at this point exclude the possibility that AIP in children may yet follow a distinct disease pattern.
A total of 27% of children and 10-20% of adults ( 5 ) diagnosed with AIP have concurrent immune/infl ammatory diseases, especially ulcerative colitis. It remains to be elucidated whether the pancreas infl ammation drives the intestinal infl ammation in these cases or whether the intestinal infl ammation spreads to the pancreas.
Th e current standard treatment for AIP is corticosteroid therapy. Th e therapeutic approach to AIP has signifi cantly evolved over time. In the early days, surgery was undertaken to confi rm the nature of a pancreatic mass and/or drain an obstructed bile duct. ERCP was used for CBD stenting in children with obstructive jaundice. Th is approach has now mainly been replaced by a trial of corticosteroid therapy. Th e corticosteroid induction dose used in children (1-1.5 mg/kg/day) as captured in our study was higher than the recommended dose (0.6-1 mg/kg/day) in adults with AIP. Of the children, 92% clinically improved with corticosteroids. Interestingly, 17% of the AIP patients had disease resolution without any treatment. Although corticosteroid use seems benefi cial in the short term in adults with AIP, it remains unclear whether it has an impact on the long-term outcome of patients ( 29 ) . In the absence of any comparative or outcome studies in children, we believe that a time-limited corticosteroid treatment course to treat the acute symptoms of pancreatitis, which may also prevent long-term complications of pancreatic insuffi ciency, is justifi ed. However, further studies are needed to determine whether 
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Autoimmune pancreatitis (AIP) is a distinctive type of pancreatitis that can also occur in children.
✓ Disease-specifi c diagnostic criteria have been developed for AIP in adults, but not for children.
WHAT IS NEW HERE
✓ Pediatric AIP has a distinct presentation with features similar to type 2 AIP in adults.
✓ Abdominal pain is the most common symptom and serum
IgG4 is rarely elevated in children with AIP.
✓ The diagnosis of pediatric AIP can be made based on typical clinical presentation and imaging fi ndings.
the advantages of steroid therapy outbalance the potential side eff ects of this therapy, particularly in children. In this regard, it will be helpful to obtain control imaging about 3 months aft er starting corticosteroids to evaluate for normalization of the pancreatic imaging fi ndings, confi rming the diagnosis of AIP. Th is study comprises the most comprehensive collection of new AIP cases in children based on a multicenter collaboration. INSP-PIRE started enrolling children with acute recurrent pancreatitis and CP in 2012, gathering diagnostic and longitudinal follow-up data to elucidate the natural history of pancreatitis of diff erent etiologies. In order to ensure a complete collection of AIP cases and to prevent center-specifi c biases in establishing a diagnosis of AIP, we not only searched the INSPPIRE database with respect to specifi c MRCP fi ndings such as pancreatic masses and biliary strictures, but also additionally asked individual investigators for reevaluation of all patients with a diagnosis of AIP to confi rm the diagnosis.
Th e main limitations of this study are the limited data on midand long-term outcome especially with respect to the exocrine and endocrine pancreas function, and also regarding the development of other immune/infl ammatory conditions. For some patients, other causes of pancreatitis including genetic forms were not completely excluded. However, recent adult data have shown that the presence of mutations in pancreatitis-related genes and AIP are not mutually exclusive ( 30, 31 ) .
In conclusion, AIP is a unique form of pancreatitis. Pediatric AIP has a distinct presentation with features similar to type 2 AIP in adults. Th e diagnosis of pediatric AIP relies on the combination of clinical symptoms and distinct pancreatic parenchymal, pancreatic duct, and/or bile duct imaging abnormalities, possibly complemented with histopathological fi ndings. Th e primary choice of therapy is corticosteroids with potential long-term sequelae that include exocrine pancreatic insuffi ciency and diabetes. We hope that our summary will lead to improved recognition of AIP in children, thus paving the way for future multicentric prospective studies.
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